Axol Bioscience Acquires Phenocell to Advance Human Disease Models
October 21 2024 - 4:18AM
Business Wire
Acquisition expands Axol’s iPSC-derived cell
models and service offering to include ophthalmology and
dermatology
Axol Bioscience Ltd. (Axol), a leading induced pluripotent stem
cell (iPSC) technology provider for drug discovery, today announced
it has fully acquired Phenocell SAS, a pioneer in iPSC-based
products and bioassays for skin and retinal disorders.
The acquisition extends Axol’s portfolio of iPSC-derived cell
models, adding skin and human retinal iPSC-derived cell lines to
its existing neuroscience, pain and touch, and cardiovascular
products and services. Phenocell’s offering includes market-leading
human iPSC-derived sebocytes and retinal pigment epithelium (RPE)
and photoreceptor cells. Additionally, the company provides custom,
skin and dry age-related macular degeneration (AMD) services to
support drug discovery companies.
Liam Taylor, CEO, Axol Bioscience, said: “Axol has
previously operated in three areas of drug research and discovery:
neuroscience, pain and touch, and cardiovascular drug discovery.
This acquisition enables us to extend our product portfolio into
ophthalmology and dermatology and offer iPSC-based skin and vision
loss models. We are delighted to welcome Phenocell to the Axol
Bioscience family and look forward to building an even wider range
of advanced in vitro models of human disease, combining our shared
values and passion to accelerate drug discovery.”
“We have built a unique set of products and services over the
last decade to meet the growing requirements from the drug
discovery and cosmetic industries to move from primary models to
more consistent, human iPSC-derived models,” said Brigitte
Onteniente, CEO and founder of Phenocell. “As part of Axol
Bioscience we look forward to working with Liam and the team to
develop a larger range of models, to serve a wider market.”
Financial terms of the agreement are not disclosed.
For more information on Axol, please visit
https://axolbio.com/
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241021648590/en/
Sarah Jeffery Tel: +44 (0)7771 730 919 E-mail:
sarah.jeffery@zymecommunications.com